tiprankstipranks
Jasper Therapeutics Advances in Antibody Therapy Development
Company Announcements

Jasper Therapeutics Advances in Antibody Therapy Development

Jasper Therapeutics, Inc. ( (JSPR) ) has released its Q3 earnings. Here is a breakdown of the information Jasper Therapeutics, Inc. presented to its investors.

Don't Miss Our Christmas Offers:

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117), to treat mast cell and stem cell diseases, such as chronic urticaria and asthma, with ongoing clinical studies for these conditions.

In the third quarter of 2024, Jasper Therapeutics reported significant milestones in their mast cell development programs, including positive initial data from the SPOTLIGHT study for chronic inducible urticaria and regulatory clearance for further studies in asthma and chronic urticaria. Additionally, they announced the closure of their legacy clinical study in lower-risk myelodysplastic syndromes.

Key financial highlights from the quarter include a net loss of $18.6 million, with research and development expenses totaling $14.5 million and general and administrative expenses amounting to $5.4 million. The company holds $92.5 million in cash and cash equivalents. Strategically, the company is advancing its SPOTLIGHT and BEACON studies, expanding to higher dose cohorts, and preparing for future presentations of data in early 2025.

Despite reporting a net loss, Jasper Therapeutics continues to make progress in its clinical programs, with an optimistic outlook on upcoming data presentations and further development of briquilimab as a treatment for chronic urticaria and asthma.

Related Articles
Radhika Saraogi3 Best Stocks to Buy Now, 12/24/2024, According to Top Analysts 
TheFlyJasper Therapeutics initiated with an Outperform at BMO Capital
TheFlyJasper: First patient dosed in ETESIAN clinical study of briquilimab in asthma
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App